Facebook
Twitter
LinkedIn
ForwardJonathan Riess, MD, MS
Dr. Riess is an Associate Professor of Medicine in the Division of Hematology Oncology and Medical Director of Thoracic Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). Dr. Riess' research interests encompass novel diagnostics, targeted therapies and immunotherapies in lung cancer and other thoracic malignancies. He is the past recipient of the National Cancer Institute Cancer Clinical Investigator Team Leadership Award given to researchers who are working to improve the lives of people with cancer through extensive involvement in NCI-funded collaborative clinical trials and whose leadership, participation and activities promote clinical trials and research. He is also the past (co)recipient of the Addario Lung Cancer Foundation and Van Auken Foundation Young Innovators Team Award.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GenentechTopic:Advisory BoardDate added:10/15/2022Date updated:04/23/2024Relationship end date:07/01/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BlueprintTopic:ConsultingDate added:10/15/2022Date updated:04/23/2024Relationship end date:03/31/2021
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Boehringer IngelheimTopic:ConsultingDate added:10/15/2022Date updated:04/23/2024Relationship end date:10/01/2021
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:RegeneronTopic:Advisory Board/ConsultingDate added:10/15/2022Date updated:04/23/2024Relationship end date:08/01/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:SanofiTopic:Advisory BoardDate added:10/15/2022Date updated:04/23/2024Relationship end date:10/12/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Jazz PharmaceuticalsTopic:Advisory BoardDate added:10/15/2022Date updated:04/23/2024Relationship end date:06/22/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:NovartisTopic:ConsultingDate added:10/15/2022Date updated:04/23/2024Relationship end date:08/24/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BiodesixTopic:Advisory BoardDate added:10/15/2022Date updated:04/23/2024Relationship end date:08/01/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:EMD SeranoTopic:Advisory BoardDate added:10/15/2022Date updated:04/23/2024Relationship end date:01/27/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Boehringer IngelheimTopic:ConsultingDate added:10/15/2022Date updated:04/23/2024Relationship end date:09/21/2022